科迈迪克斯
CRMD
7.26
-0.20
-2.68%
科迈迪克斯
US · CRMD
#3663 按市值排名
7.26
-0.20
-2.68%
实时 - 追踪5344个代码 - 心跳于201秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.8个百分点。
机构持股
- 机构持股比例
- 57.00% -0.75pp
- 机构数量
- 222 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund39.08%
VC/PE Fund8.05%
Individual/Insider7.42%
Hedge Fund5.27%
Public Company1.97%
Private Company1.59%
Government Pension Fund0.69%
Insurance Company0.25%
Other35.63%
主要股东 截至 2026-06-30
BlackRock
8.11% · 6.32M 股
Deep Track Capital, LP
8.05% · 6.27M 股
Shaibatalhamd Abdalkader
5.93% · 4.62M 股
Vanguard Capital Management, LLC
4.64% · 3.62M 股
State Street Global Advisors
2.97% · 2.32M 股
Royce & Associates, LP
2.79% · 2.18M 股
UBS Asset Management
2.56% · 1.99M 股
Geode Capital Management, LLC
2.50% · 1.95M 股
Oberweis Asset Management, Inc.
1.70% · 1.32M 股
Alyeska Investment Group, L.P.
1.09% · 850.00K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 21次买入 · 29次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Joseph Todisco | Chief Executive Officer | 0.51% |
| Myron Kaplan | Independent Chairperson | 0.30% |
| Kaufman Zelnick | Executive Vice President | 0.13% |
| Steven Lefkowitz | Independent Director | 0.13% |
| Janet Dillione | Independent Director | 0.11% |
| Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | 0.11% |
| Alan Dunton | Independent Director | 0.05% |
| Gregory Duncan | Independent Director | 0.05% |
| Robert Stewart | Independent Director | 0.05% |
| Matthew David | Chief Financial Officer | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-17 | Janet Dillione | Independent Director | Derivative Exercise and Retained | +48,909 | -- |
| 2026-08-28 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Sale to Issuer | -8,076 | $8.30 |
| 2026-08-28 | Susan Blum | EVP & Chief Financial Officer | Sale to Issuer | -8,424 | $8.30 |
| 2026-08-28 | Kaufman Zelnick | Executive Vice President | Sale to Issuer | -8,424 | $8.30 |
| 2026-02-03 | Joseph Todisco | Chief Executive Officer | Other Acquisition | +77,156 | -- |
| 2026-02-03 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Other Acquisition | +36,006 | -- |
| 2026-02-03 | Kaufman Zelnick | Executive Vice President | Other Acquisition | +36,006 | -- |
| 2026-01-25 | Myron Kaplan | Independent Chairperson | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Alan Dunton | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Janet Dillione | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Steven Lefkowitz | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Robert Stewart | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-25 | Gregory Duncan | Independent Director | Other Acquisition | +30,453 | -- |
| 2026-01-22 | Joseph Todisco | Chief Executive Officer | Sale to Issuer | -27,306 | $7.27 |
| 2026-01-22 | Joseph Todisco | Chief Executive Officer | Other Acquisition | +225,900 | -- |
| 2026-01-22 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Sale to Issuer | -10,778 | $7.27 |
| 2026-01-22 | Elizabeth Masson-Hurlburt | Executive VP and Head of Clinical & Medical Affairs | Other Acquisition | +93,010 | -- |
| 2026-01-22 | Susan Blum | EVP & Chief Financial Officer | Sale to Issuer | -9,767 | $7.27 |
| 2026-01-22 | Susan Blum | EVP & Chief Financial Officer | Other Acquisition | +72,820 | -- |
| 2026-01-22 | Kaufman Zelnick | Executive Vice President | Sale to Issuer | -8,803 | $7.27 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:25 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
科迈迪克斯 讨论区 0 条评论